Guardant Health, Inc. (NASDAQ:GH – Get Rating)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $24.20 and last traded at $25.11, with a volume of 248119 shares changing hands. The stock had previously closed at $25.01.
Analyst Ratings Changes
A number of equities analysts have recently weighed in on GH shares. Bank of America upped their price target on shares of Guardant Health from $65.00 to $70.00 in a research note on Friday, December 16th. The Goldman Sachs Group reduced their price target on shares of Guardant Health from $70.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, February 6th. Morgan Stanley reduced their price target on shares of Guardant Health from $73.00 to $66.00 and set an “overweight” rating for the company in a research report on Monday, February 27th. Scotiabank assumed coverage on Guardant Health in a research note on Wednesday, January 4th. They issued a “sector outperform” rating and a $36.00 price objective for the company. Finally, JPMorgan Chase & Co. dropped their price objective on Guardant Health from $75.00 to $65.00 and set an “overweight” rating for the company in a research note on Friday, February 24th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, Guardant Health presently has a consensus rating of “Moderate Buy” and an average price target of $57.64.
Guardant Health Stock Up 3.2 %
The company has a debt-to-equity ratio of 18.90, a current ratio of 6.17 and a quick ratio of 5.90. The firm has a 50-day simple moving average of $29.52 and a two-hundred day simple moving average of $41.10. The company has a market cap of $2.74 billion, a PE ratio of -4.17 and a beta of 0.86.
Institutional Investors Weigh In On Guardant Health
About Guardant Health
Guardant Health, Inc is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H.
- Get a free copy of the StockNews.com research report on Guardant Health (GH)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.